GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medivir AB (OSTO:MVIR) » Definitions » Short Percentage of Float

Medivir AB (OSTO:MVIR) Short Percentage of Float


View and export this data going back to 1996. Start your Free Trial

What is Medivir AB Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Medivir AB's Short Percentage of Float

For the Biotechnology subindustry, Medivir AB's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medivir AB's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medivir AB's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Medivir AB's Short Percentage of Float falls into.


;
;

Medivir AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medivir AB (OSTO:MVIR) » Definitions » Short Percentage of Float
Comparable Companies
OSTO:ISOFOL OSTO:INIT XSAT:CURAS NGM:GTAB B OSTO:ALZCUR OSTO:ALZ OSTO:CLBIO OSTO:ANNX OSTO:IMMU OSTO:KDEV VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
0GP7:UK MVR0:Germany
Address
Lunastigen 5, PO Box 1086, 2nd floor, Huddinge, SWE, 141 22
Website
https://www.medivir.com
Medivir AB develops drugs with a focus on cancer, where unmet medical needs are high. The company is concentrating on the development of fostroxacitabine bralpamide (fostrox), a liver-targeted inhibitor of DNA replication that selectively delivers the cell-killing agent to the tumor while minimizing potentially harmful effects on normal cells. It has developed two pharmaceutical products: Xerclear, used for treating labial herpes (cold sores), and Olysio, which have reached the market. Medivir also has various out-licensed projects, such as MIV-701, birinapant, USP-1/TNG348, USP-7, and MBLI/MET-X, as well as two other drug projects, remetinostat and MIV-711, in the clinical development phase. Geographically, it generates its maximum revenue from Europe and other regions.

Medivir AB Headlines

No Headlines